SequelSEC

Harvard Apparatus Regenerative Technology, Inc. HRGN

Surgical & Medical Instruments & Apparatus · CIK 0001563665 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$982.00K
Fiscal year ended 2026-06-30
Operating income
-$6.71M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$15.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.89Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue22.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity14.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue285.5%95th
Gross margin8.2%6th
Operating margin-982.2%10th
Net margin-975.7%11th
Revenue YoY growth63.7%89th
R&D / revenue376.8%88th
Current ratio1.19x18th

Harvard Apparatus Regenerative Technology, Inc. (HRGN) reported revenue of $982.00K and net income of -$6.68M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Harvard Apparatus Regenerative Technology, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

Harvard Apparatus Regenerative Technology, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$982.00K
Cost of revenue$908.00K
Gross profit$74.00K
Operating income-$6.71M
Net income-$6.68M
Research & development$2.87M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$3.83M
Selling & marketingUnavailable

Balance

Harvard Apparatus Regenerative Technology, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$351.00K
Total assets$1.68M
Current assets$789.00K
Total liabilities$3.06M
Current liabilities$3.04M
Total equity incl. NCI-$1.38M
Temporary (mezzanine) equityUnavailable
Inventory$0
Accounts receivable$9.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$757.00K

Cash flow

Harvard Apparatus Regenerative Technology, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$3.64M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flowUnavailable
Net change in cash-$435.00K
Stock-based compensation$1.84M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Harvard Apparatus Regenerative Technology, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin7.5%
Operating margin-683.3%
FCF marginUnavailable
SBC / revenue187.7%
Current ratio0.26x
Revenue YoY growth44.6%
Net margin-680.5%
R&D / revenue291.9%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HRGN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.